Zometa and Vitreous detachment - a phase IV clinical study of FDA data

Summary:

Vitreous detachment is reported as a side effect among people who take Zometa (zoledronic acid), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Aredia, and have Osteoporosis.

The phase IV clinical study analyzes which people have Vitreous detachment when taking Zometa. It is created by eHealthMe based on reports of 71,074 people who have side effects when taking Zometa from the FDA, and is updated regularly.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

What is Vitreous detachment?

Vitreous detachment (a condition of the eye in which the vitreous humour separates from the retina) is found to be associated with 410 drugs and 457 conditions by eHealthMe. Check the latest studies of Vitreous detachment.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

71,074 people reported to have side effects when taking Zometa.
Among them, 88 people (0.12%) have Vitreous detachment.

Among these 88 people:

How long have people been on Zometa when they have Vitreous detachment? *

What is the gender of people who have Vitreous detachment when taking Zometa? *

female: 83.72 %
male: 16.28 %

What is the age of people who have Vitreous detachment when taking Zometa? *

What are other drugs people take besides Zometa? *

What are other side effects people have besides Vitreous detachment? *

Osteomyelitis (infection of bone): 80 people, 90.91%
Pain: 74 people, 84.09%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 73 people, 82.95%
Osteonecrosis Of Jaw (death of bone of jaw): 68 people, 77.27%
Bone Disorder: 66 people, 75.00%
Sinusitis (inflammation of sinus): 63 people, 71.59%
Abdominal Pain: 57 people, 64.77%
Spinal Osteoarthritis (joint cartilage loss in spine): 56 people, 63.64%
Rotator Cuff Syndrome (a spectrum of conditions affecting the rotator cuff tendons of the shoulder): 54 people, 61.36%
Tooth Abscess (pus formation in tooth): 53 people, 60.23%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 29 people, 32.95%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 25 people, 28.41%
Toothaches (tooth pain): 11 people, 12.50%
Thrombocytopenia (decrease of platelets in blood): 11 people, 12.50%
Muscle Spasms (muscle contraction): 11 people, 12.50%
Metastases To Bone (cancer spreads to bone): 5 people, 5.68%
Depression: 4 people, 4.55%
High Blood Pressure: 4 people, 4.55%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 4 people, 4.55%
Bone Neoplasm Malignant (cancer of bone): 3 people, 3.41%

* Approximation only. Some reports may have incomplete information.

Do you take Zometa and have Vitreous detachment?

- Check whether Vitreous detachment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zometa:

Zometa (71,434 reports)

Browse all side effects of Zometa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous detachment:

Vitreous detachment (410 drugs)

Browse all the conditions that are associated with Vitreous detachment:

Vitreous detachment (457 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zometa) and Zometa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.